TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has issued an update.
Clarity Pharmaceuticals announced that their Co-PSMA trial achieved its primary endpoint, demonstrating that 64Cu-SAR-bisPSMA detects significantly more prostate cancer lesions than the standard-of-care 68Ga-PSMA-11 PET/CT in patients with low PSA levels. This success supports the potential of 64Cu-SAR-bisPSMA to become a new standard in PSMA PET imaging, potentially expanding the market by enabling earlier detection of prostate cancer, which could improve patient outcomes and guide more informed treatment decisions.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$9.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve cancer treatment outcomes. Their primary product, 64Cu-SAR-bisPSMA, is a Targeted Copper Theranostic (TCT) used for imaging and therapy in prostate cancer, leveraging proprietary SAR technology to securely hold copper isotopes.
Average Trading Volume: 3,466,625
Technical Sentiment Signal: Buy
Current Market Cap: A$2.12B
Find detailed analytics on CU6 stock on TipRanks’ Stock Analysis page.